Daily Medication Pearl: Lifitegrast Ophthalmic Solution (Xiidra)

Medication Pearl of the Day: Lifitegrast Ophthalmic Solution (Xiidra)

Indication: Lifitegrast ophthalmic solution (Xiidra) 5% is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the treatment of the signs and symptoms of dry eye disease (DED).

Insight:

• Dosing: One drop twice daily in each eye (approximately 12 hours apart).
• Dosage forms: Ophthalmic solution containing lifitegrast 5% (50 mg/mL).
• Adverse events: The most common adverse reactions (incidence 5%-25%) following the use of Xiidra were instillation site irritation, dysgeusia, and decreased visual acuity.
• Mechanism of action: Lifitegrast binds to the integrin LFA-1, a cell surface protein found on leukocytes and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1).
• Manufacturer: Shire

Sources:

label (fda.gov)

xiidra image - Google Search